The company said that the antibody blockers “significantly reduced” allergy symptoms compared to a placebo in the trials.
Regeneron Pharmaceuticals, Inc. (REGN) said on Monday that its experimental therapy significantly reduced symptoms of cat and birch allergies in late-stage trials, successfully meeting their key endpoints.
Add Asianet Newsable as a Preferred Source
In the trials, patients with moderate to severe cat or birch allergies received direct instillation of either cat dander or birch pollen into the eyes, followed by a single subcutaneous administration of the allergen-blocking antibodies. The antibody blockers “significantly reduced” allergy symptoms compared to placebo, the company said.
Get updates to this developing story <directly on Stocktwits.<
